Semaglutide
$74.76 – $246.84
Semaglutide vs Tirzepatide: Research Comparison
Reference comparison for laboratory researchers. All material on this page is for in-vitro and investigational research only.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Compound class | GLP-1 receptor agonist | Dual GIP / GLP-1 receptor agonist |
| Receptor profile | GLP-1 only | GIP + GLP-1 |
| Molecular type | Peptide (analog) | Peptide (dual agonist) |
| Typical route / frequency | Once-weekly subcutaneous | Once-weekly subcutaneous |
| CAS reference | 910463-68-2 | 2023788-19-2 |
Tirzepatide
$46.20 – $406.56
Key Differences
- Semaglutide signals through the GLP-1 receptor only; tirzepatide is engineered to engage both GIP and GLP-1 receptors.
- The difference is receptor scope, not a ranking of outcome between the two molecules.
- Both are peptide-based and dosed weekly in clinical research settings.
Evidence and Limitations
Clinical research: both compounds have published human clinical trial programs (Eli Lilly / Novo Nordisk sponsored).
Mechanism: receptor profiles are established from receptor-binding and pharmacology studies.
Limitations: this page describes mechanism and research status only. It does not compare efficacy, dosing for any individual, or suitability for any use.
Research Notes
Browse the Metabolic Research category, or view batch documentation for Semaglutide and Tirzepatide. All AminoForge material is supplied as a lyophilized research vial with an independently HPLC-verified batch record, for laboratory research use only.